Reuters, like many other media outlets, covered Novo Nordisk’s request that the FDA add semaglutide to the Demonstrably Difficult to Compound list. (Silly, we know.)
It quoted APC pointing out that there’s a big difference between creating the semaglutide molecule (tough) and compounding with it (easy).